SM-Youtube

Year	Number of Results
2003	5
2006	4
2007	4
2008	6
2009	10
2010	8
2011	23
2012	20
2013	21
2014	25
2015	48
2016	32
2017	37
2018	57
2019	59
2020	66
2021	72
2022	90
2023	72
2024	32

1

Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Walsh SL, et al. Drug Alcohol Depend. 2016 May 1;162:190-8. doi: 10.1016/j.drugalcdep.2016.03.005. Epub 2016 Mar 14. Drug Alcohol Depend. 2016. PMID: 27012435 Free PMC article. Clinical Trial.

2

Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision.

Elarabi HF, Hasan N, Marsden J, Radwan D, Adem A, Almamari S, Elrasheed A. Elarabi HF, et al. Pharmacopsychiatry. 2020 Apr;53(3):115-121. doi: 10.1055/a-1083-6842. Epub 2020 Jan 30. Pharmacopsychiatry. 2020. PMID: 32000269

3

Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.

Coe MA, Lofwall MR, Walsh SL. Coe MA, et al. J Addict Med. 2019 Mar/Apr;13(2):93-103. doi: 10.1097/ADM.0000000000000457. J Addict Med. 2019. PMID: 30531584 Free PMC article. Review.

4

Post marketing surveillance of sublingual buprenorphine naloxone combination tablets.

Ray R, Vaswani M, Deb KS, Sethi H, Chopra A, Kishore N, Goyal R. Ray R, et al. Indian J Physiol Pharmacol. 2012 Oct-Dec;56(4):359-66. Indian J Physiol Pharmacol. 2012. PMID: 23781656

5

Buprenorphine-naloxone.

Hu T, Nijmeh L, Pyle A. Hu T, et al. CMAJ. 2018 Nov 26;190(47):E1389. doi: 10.1503/cmaj.180776. CMAJ. 2018. PMID: 30478217 Free PMC article. No abstract available.

6

Unusual Drug Test Results for a Patient on Buprenorphine and Naloxone.

Gall B, El-Khoury JM. Gall B, et al. Clin Chem. 2019 Oct;65(10):1332-1333. doi: 10.1373/clinchem.2019.309484. Clin Chem. 2019. PMID: 31570415 No abstract available.

7

Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.

Randhawa PA, Brar R, Nolan S. Randhawa PA, et al. CMAJ. 2020 Jan 20;192(3):E73. doi: 10.1503/cmaj.74018. CMAJ. 2020. PMID: 31959660 Free PMC article. No abstract available.

8

Should emergency departments be prescribing buprenorphine/naloxone?

Bhat C, Zworth M, Rosenberg H. Bhat C, et al. CJEM. 2023 Oct;25(10):787-788. doi: 10.1007/s43678-023-00594-z. CJEM. 2023. PMID: 37805957 No abstract available.

9

Buprenorphine-Naloxone Maintenance and Lactation.

Jansson LM, McConnell K, Velez M, Spencer N, Gomonit M, Swortwood MJ. Jansson LM, et al. J Hum Lact. 2024 Feb;40(1):113-119. doi: 10.1177/08903344231209304. Epub 2023 Nov 29. J Hum Lact. 2024. PMID: 38018534

10

No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.

Kosloski MP, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W. Kosloski MP, et al. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00958-17. doi: 10.1128/AAC.00958-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28807904 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

589 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Search Results

589 results

Results by year